• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.

作者信息

Garfield David H

机构信息

Department of Medicine, University of Colorado Health Sciences Center, Aurora, CA, USA.

出版信息

J Clin Oncol. 2005 Oct 20;23(30):7738-40. doi: 10.1200/JCO.2005.02.4471.

DOI:10.1200/JCO.2005.02.4471
PMID:16234533
Abstract
摘要

相似文献

1
Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.肺癌的现代治疗：病例2。一名晚期非小细胞肺癌患者在吉非替尼治疗失败后对厄洛替尼的反应。
J Clin Oncol. 2005 Oct 20;23(30):7738-40. doi: 10.1200/JCO.2005.02.4471.
2
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.当前情况：厄洛替尼（特罗凯）和吉非替尼（易瑞沙）在非小细胞肺癌中的应用
Oncologist. 2005 Aug;10(7):467-70. doi: 10.1634/theoncologist.10-7-467.
3
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.一项在既往化疗失败的晚期非小细胞肺癌患者中比较吉非替尼和厄洛替尼疗效的随机 II 期临床研究。
Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.
4
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.中国非小细胞肺癌患者表皮生长因子受体酪氨酸激酶结构域的吉非替尼敏感突变
Clin Cancer Res. 2005 Jun 15;11(12):4289-94. doi: 10.1158/1078-0432.CCR-04-2506.
5
Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.日本非小细胞肺癌患者接受表皮生长因子受体（EGFR）靶向酪氨酸激酶抑制剂吉非替尼治疗时的血浆巨噬细胞炎症蛋白-1β（MIP-1β）水平与皮肤毒性
Lung Cancer. 2005 Dec;50(3):393-9. doi: 10.1016/j.lungcan.2005.07.012. Epub 2005 Sep 8.
6
Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.尝试用所有碎片拼凑拼图：非小细胞肺癌中的表皮生长因子受体酪氨酸激酶抑制剂
J Cell Physiol. 2005 Dec;205(3):355-63. doi: 10.1002/jcp.20402.
7
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.先前对吉非替尼有应答的晚期非小细胞肺癌患者化疗后吉非替尼重新治疗的前瞻性研究。
Clin Lung Cancer. 2012 Nov;13(6):458-63. doi: 10.1016/j.cllc.2012.01.006. Epub 2012 Mar 7.
8
[New era in cancer therapy. Gefitinib: small molecule--strong action].癌症治疗的新时代。吉非替尼：小分子——强大作用
MMW Fortschr Med. 2004 Nov 18;146(47):70-1.
9
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).选择性表皮生长因子受体抑制剂厄洛替尼（特罗凯）和吉非替尼（易瑞沙）的当前认知与未来方向
Oncologist. 2005 Sep;10(8):579-89. doi: 10.1634/theoncologist.10-8-579.
10
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.比较吉非替尼和厄洛替尼作为三线治疗晚期非小细胞肺癌的疗效。
Eur J Cancer. 2013 Jan;49(1):106-14. doi: 10.1016/j.ejca.2012.07.014. Epub 2012 Aug 14.

引用本文的文献

1
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.肺腺癌初始携带有敏感 EGFR 突变，一线吉非替尼和二线细胞毒化疗获得性耐药。
BMC Pharmacol Toxicol. 2017 May 10;18(1):21. doi: 10.1186/s40360-017-0130-0.
2
Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor.台湾曾吸烟的IV期肺腺癌女性患者再次接受酪氨酸激酶抑制剂治疗后预后较差。
Onco Targets Ther. 2016 Mar 15;9:1511-8. doi: 10.2147/OTT.S100169. eCollection 2016.
3
Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.
吉非替尼一线治疗失败后厄洛替尼用于晚期非小细胞肺癌的临床观察及文献复习
World J Clin Oncol. 2014 Dec 10;5(5):858-64. doi: 10.5306/wjco.v5.i5.858.
4
Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma.一名肺腺癌患者使用厄洛替尼治疗后截瘫症状得以恢复。
Contemp Oncol (Pozn). 2014;18(2):140-2. doi: 10.5114/wo.2014.41393. Epub 2014 Jun 3.
5
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.T790M 和 EGFR TKI 的获得性耐药：临床报告的文献回顾。
J Thorac Dis. 2011 Mar;3(1):10-8. doi: 10.3978/j.issn.2072-1439.2010.12.02.
6
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌患者的临床反应：一项回顾性分析。
BMC Cancer. 2011 Jan 1;11:1. doi: 10.1186/1471-2407-11-1.
7
Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.韩国不吸烟女性肺腺癌患者吉非替尼治疗后序贯厄洛替尼的疗效观察
Cancer Res Treat. 2007 Mar;39(1):37-9. doi: 10.4143/crt.2007.39.1.37. Epub 2007 Mar 31.
8
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.厄洛替尼作为一线吉非替尼治疗失败后的挽救治疗在非小细胞肺癌中的应用。
Cancer Chemother Pharmacol. 2010 May;65(6):1023-8. doi: 10.1007/s00280-009-1107-5. Epub 2009 Aug 13.
9
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.厄洛替尼对吉非替尼耐药的表皮生长因子受体（EGFR）突变型非小细胞肺癌的疗效
Clin Cancer Res. 2008 Nov 1;14(21):7060-7. doi: 10.1158/1078-0432.CCR-08-1455.
10
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.厄洛替尼作为吉非替尼治疗失败后的非小细胞肺癌患者挽救治疗的II期研究。
Ann Oncol. 2008 Dec;19(12):2039-42. doi: 10.1093/annonc/mdn423. Epub 2008 Jul 21.